Ryan Feldman1,2,3,4, Matthew Stanton5,6,7,8, Elizabeth M Suelzer9. 1. The Wisconsin Poison Center, Milwaukee, USA. ryan.feldman@froedtert.com. 2. School of Pharmacy, The Medical College of Wisconsin, Milwaukee, USA. ryan.feldman@froedtert.com. 3. Department of Emergency Medicine, The Medical College of Wisconsin, Milwaukee, USA. ryan.feldman@froedtert.com. 4. Department of Pharmacy, Froedtert Hospital, Milwaukee, USA. ryan.feldman@froedtert.com. 5. The Wisconsin Poison Center, Milwaukee, USA. 6. School of Pharmacy, The Medical College of Wisconsin, Milwaukee, USA. 7. Department of Emergency Medicine, The Medical College of Wisconsin, Milwaukee, USA. 8. Department of Pharmacy, Froedtert Hospital, Milwaukee, USA. 9. The Medical College of Wisconsin Libraries, Milwaukee, USA.
Abstract
BACKGROUND: Vitamin E acetate (VEA) has come under significant scrutiny due to its association with E-cigarette or vaping product use-associated lung injury (EVALI). Various theoretical mechanisms have been proposed for toxicity, including tocopherol (vitamin E)-mediated surfactant damage, recruitment of inflammation, and pyrolysis of acetate to the pulmonary irritant ketene. OBJECTIVE: Characterize studies in mammals evaluating inhaled VEA, vitamin E analogues, or pyrolyzed acetate that describe subsequent effects on the lung. ELIGIBILITY: Research in all languages from time of inception to October 1, 2020, regarding mammals (human or animal) exposed to inhaled vitamin E analogues, or any compound containing acetate administered via inhalation after pyrolysis, and subsequent description of pulmonary effect. SOURCES OF EVIDENCE: Ovid MEDLINE, Scopus, and Web of Science Core Collection. RESULTS: In total, 786 unique articles were identified. After duplicate reviewer screening, 16 articles were eligible for inclusion. Tocopherol was evaluated in 68.8% (11/16) of the studies, VEA in 18.8% (3/16), and both VEA and tocopherol were evaluated in 12.5% (2/16). Of the five studies evaluating VEA, it was given by pyrolysis in 60.0% (3/5). No human studies were identified. All included trials were conducted on non-human mammals: 75.0% (12/16) rodent models and 25.0% (4/16) sheep models. Outcomes assessed were heterogeneous and included 57 unique outcomes. CONCLUSIONS: Several questions still exist regarding the pulmonary toxicity of inhaled tocopherol and VEA. More studies are needed to determine whether tocopherol alone (i.e., without acetate) can cause pulmonary injury. Additionally, further studies of VEA should evaluate the impact that pyrolysis and co-administration with other compounds, such as tetrahydrocannabinol, have on the toxic potential of VEA.
BACKGROUND: Vitamin E acetate (VEA) has come under significant scrutiny due to its association with E-cigarette or vaping product use-associated lung injury (EVALI). Various theoretical mechanisms have been proposed for toxicity, including tocopherol (vitamin E)-mediated surfactant damage, recruitment of inflammation, and pyrolysis of acetate to the pulmonary irritant ketene. OBJECTIVE: Characterize studies in mammals evaluating inhaled VEA, vitamin E analogues, or pyrolyzed acetate that describe subsequent effects on the lung. ELIGIBILITY: Research in all languages from time of inception to October 1, 2020, regarding mammals (human or animal) exposed to inhaled vitamin E analogues, or any compound containing acetate administered via inhalation after pyrolysis, and subsequent description of pulmonary effect. SOURCES OF EVIDENCE: Ovid MEDLINE, Scopus, and Web of Science Core Collection. RESULTS: In total, 786 unique articles were identified. After duplicate reviewer screening, 16 articles were eligible for inclusion. Tocopherol was evaluated in 68.8% (11/16) of the studies, VEA in 18.8% (3/16), and both VEA and tocopherol were evaluated in 12.5% (2/16). Of the five studies evaluating VEA, it was given by pyrolysis in 60.0% (3/5). No human studies were identified. All included trials were conducted on non-human mammals: 75.0% (12/16) rodent models and 25.0% (4/16) sheep models. Outcomes assessed were heterogeneous and included 57 unique outcomes. CONCLUSIONS: Several questions still exist regarding the pulmonary toxicity of inhaled tocopherol and VEA. More studies are needed to determine whether tocopherol alone (i.e., without acetate) can cause pulmonary injury. Additionally, further studies of VEA should evaluate the impact that pyrolysis and co-administration with other compounds, such as tetrahydrocannabinol, have on the toxic potential of VEA.
Entities:
Keywords:
E-Cigarette; EVALI; Vaping; Vitamin E; Vitamin E Acetate
Authors: Atsumori Hamahata; Perenlei Enkhbaatar; Edward R Kraft; Matthias Lange; Scott W Leonard; Maret G Traber; Robert A Cox; Frank C Schmalstieg; Hal K Hawkins; Elbert B Whorton; Eszter M Horvath; Csaba Szabo; Lillian D Traber; David N Herndon; Daniel L Traber Journal: Free Radic Biol Med Date: 2008-05-03 Impact factor: 7.376
Authors: Benjamin C Blount; Mateusz P Karwowski; Peter G Shields; Maria Morel-Espinosa; Liza Valentin-Blasini; Michael Gardner; Martha Braselton; Christina R Brosius; Kevin T Caron; David Chambers; Joseph Corstvet; Elizabeth Cowan; Víctor R De Jesús; Paul Espinosa; Carolina Fernandez; Cory Holder; Zsuzsanna Kuklenyik; Jennifer D Kusovschi; Cody Newman; Gregory B Reis; Jon Rees; Chris Reese; Lalith Silva; Tiffany Seyler; Min-Ae Song; Connie Sosnoff; Carleen R Spitzer; Denise Tevis; Lanqing Wang; Cliff Watson; Mark D Wewers; Baoyun Xia; Douglas T Heitkemper; Isaac Ghinai; Jennifer Layden; Peter Briss; Brian A King; Lisa J Delaney; Christopher M Jones; Grant T Baldwin; Anita Patel; Dana Meaney-Delman; Dale Rose; Vikram Krishnasamy; John R Barr; Jerry Thomas; James L Pirkle Journal: N Engl J Med Date: 2019-12-20 Impact factor: 91.245
Authors: Mitchell DiPasquale; Omotayo Gbadamosi; Michael H L Nguyen; Stuart R Castillo; Brett W Rickeard; Elizabeth G Kelley; Michihiro Nagao; Drew Marquardt Journal: Chem Res Toxicol Date: 2020-09-04 Impact factor: 3.739